Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/37076 http://dx.doi.org/10.1371/journal.pone.0082796 |
Resumo: | Objective: We aimed to investigate the ability of natalizumab (NTZ)-treated patients to assume treatment-associated risks and the factors involved in such risk acceptance.Methods: From a total of 185 patients, 114 patients on NTZ as of July 2011 carried out a comprehensive survey. We obtained disease severity perception scores, personality traits' scores, and risk-acceptance scores (RAS) so that higher RAS indicated higher risk acceptance. We recorded JC virus status (JCV+/-), prior immunosuppression, NTZ treatment duration, and clinical characteristics. NTZ patients were split into subgroups (A-E), depending on their individual PML risk. Some 22 MS patients on first-line drugs (DMD) acted as controls.Results: No differences between treatment groups were observed in disease severity perception and personality traits. RAS were higher in NTZ than in DMD patients (p<0.01). Perception of the own disease as a more severe condition tended to predict higher RAS (p=0.07). Higher neuroticism scores predicted higher RAS in the NTZ group as a whole (p=0.04), and in high PML-risk subgroups (A-B) (p=0.02). in low PML-risk subgroups (C-E), higher RAS were associated with a JCV+ status (p=0.01). Neither disability scores nor pre-treatment relapse rate predicted RAS in either group.Conclusions: Risk acceptance is a multifactorial phenomenon, which might be partly explained by an adaptive process, in light of the higher risk acceptance amongst NTZ-treated patients and, especially, amongst those who are JCV seropositive but still have low PML risk, but which seems also intimately related to personality traits. |
id |
UFSP_5b9b272566298b106ceec831c751089e |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/37076 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Tur, CarmenTintore, MarVidal-Jordana, AngelaBichuetti, Denis [UNIFESP]Nieto Gonzalez, PabloJesus Arevalo, MariaArrambide, GeorginaAnglada, ElisendaGalan, IngridCastillo, JoaquinJordi Rio, Carlos NosIsabel Martin, MariaComabella, ManuelSastre-Garriga, JaumeMontalban, XavierVall dHebron Univ HospUniversidade Federal de São Paulo (UNIFESP)Univ Hosp Principe de Asturias2016-01-24T14:34:51Z2016-01-24T14:34:51Z2013-12-10Plos One. San Francisco: Public Library Science, v. 8, n. 12, 7 p., 2013.1932-6203http://repositorio.unifesp.br/handle/11600/37076http://dx.doi.org/10.1371/journal.pone.0082796WOS000328707400096.pdf10.1371/journal.pone.0082796WOS:000328707400096Objective: We aimed to investigate the ability of natalizumab (NTZ)-treated patients to assume treatment-associated risks and the factors involved in such risk acceptance.Methods: From a total of 185 patients, 114 patients on NTZ as of July 2011 carried out a comprehensive survey. We obtained disease severity perception scores, personality traits' scores, and risk-acceptance scores (RAS) so that higher RAS indicated higher risk acceptance. We recorded JC virus status (JCV+/-), prior immunosuppression, NTZ treatment duration, and clinical characteristics. NTZ patients were split into subgroups (A-E), depending on their individual PML risk. Some 22 MS patients on first-line drugs (DMD) acted as controls.Results: No differences between treatment groups were observed in disease severity perception and personality traits. RAS were higher in NTZ than in DMD patients (p<0.01). Perception of the own disease as a more severe condition tended to predict higher RAS (p=0.07). Higher neuroticism scores predicted higher RAS in the NTZ group as a whole (p=0.04), and in high PML-risk subgroups (A-B) (p=0.02). in low PML-risk subgroups (C-E), higher RAS were associated with a JCV+ status (p=0.01). Neither disability scores nor pre-treatment relapse rate predicted RAS in either group.Conclusions: Risk acceptance is a multifactorial phenomenon, which might be partly explained by an adaptive process, in light of the higher risk acceptance amongst NTZ-treated patients and, especially, amongst those who are JCV seropositive but still have low PML risk, but which seems also intimately related to personality traits.Bayer Health CareMerck SeronoTEVAVall dHebron Univ Hosp, Dept Neurol Neuroimmunol, Multiple Sclerosis Ctr Catalonia Cemcat, Barcelona, SpainUniversidade Federal de São Paulo, Dept Neurol & Neurosurg, São Paulo, BrazilUniv Hosp Principe de Asturias, Dept Neurol, Madrid, SpainUniversidade Federal de São Paulo, Dept Neurol & Neurosurg, São Paulo, BrazilWeb of Science7engPublic Library SciencePlos OneRisk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatmentinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALWOS000328707400096.pdfapplication/pdf257861${dspace.ui.url}/bitstream/11600/37076/1/WOS000328707400096.pdf6040f08dbe202d56c9e98c6e92b935c2MD51open accessTEXTWOS000328707400096.pdf.txtWOS000328707400096.pdf.txtExtracted texttext/plain40579${dspace.ui.url}/bitstream/11600/37076/2/WOS000328707400096.pdf.txtf4b294bc3b9ef688f2273d3dc368b202MD52open access11600/370762022-11-04 15:40:35.144open accessoai:repositorio.unifesp.br:11600/37076Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652022-11-04T18:40:35Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment |
title |
Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment |
spellingShingle |
Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment Tur, Carmen |
title_short |
Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment |
title_full |
Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment |
title_fullStr |
Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment |
title_full_unstemmed |
Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment |
title_sort |
Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment |
author |
Tur, Carmen |
author_facet |
Tur, Carmen Tintore, Mar Vidal-Jordana, Angela Bichuetti, Denis [UNIFESP] Nieto Gonzalez, Pablo Jesus Arevalo, Maria Arrambide, Georgina Anglada, Elisenda Galan, Ingrid Castillo, Joaquin Jordi Rio, Carlos Nos Isabel Martin, Maria Comabella, Manuel Sastre-Garriga, Jaume Montalban, Xavier |
author_role |
author |
author2 |
Tintore, Mar Vidal-Jordana, Angela Bichuetti, Denis [UNIFESP] Nieto Gonzalez, Pablo Jesus Arevalo, Maria Arrambide, Georgina Anglada, Elisenda Galan, Ingrid Castillo, Joaquin Jordi Rio, Carlos Nos Isabel Martin, Maria Comabella, Manuel Sastre-Garriga, Jaume Montalban, Xavier |
author2_role |
author author author author author author author author author author author author author author |
dc.contributor.institution.none.fl_str_mv |
Vall dHebron Univ Hosp Universidade Federal de São Paulo (UNIFESP) Univ Hosp Principe de Asturias |
dc.contributor.author.fl_str_mv |
Tur, Carmen Tintore, Mar Vidal-Jordana, Angela Bichuetti, Denis [UNIFESP] Nieto Gonzalez, Pablo Jesus Arevalo, Maria Arrambide, Georgina Anglada, Elisenda Galan, Ingrid Castillo, Joaquin Jordi Rio, Carlos Nos Isabel Martin, Maria Comabella, Manuel Sastre-Garriga, Jaume Montalban, Xavier |
description |
Objective: We aimed to investigate the ability of natalizumab (NTZ)-treated patients to assume treatment-associated risks and the factors involved in such risk acceptance.Methods: From a total of 185 patients, 114 patients on NTZ as of July 2011 carried out a comprehensive survey. We obtained disease severity perception scores, personality traits' scores, and risk-acceptance scores (RAS) so that higher RAS indicated higher risk acceptance. We recorded JC virus status (JCV+/-), prior immunosuppression, NTZ treatment duration, and clinical characteristics. NTZ patients were split into subgroups (A-E), depending on their individual PML risk. Some 22 MS patients on first-line drugs (DMD) acted as controls.Results: No differences between treatment groups were observed in disease severity perception and personality traits. RAS were higher in NTZ than in DMD patients (p<0.01). Perception of the own disease as a more severe condition tended to predict higher RAS (p=0.07). Higher neuroticism scores predicted higher RAS in the NTZ group as a whole (p=0.04), and in high PML-risk subgroups (A-B) (p=0.02). in low PML-risk subgroups (C-E), higher RAS were associated with a JCV+ status (p=0.01). Neither disability scores nor pre-treatment relapse rate predicted RAS in either group.Conclusions: Risk acceptance is a multifactorial phenomenon, which might be partly explained by an adaptive process, in light of the higher risk acceptance amongst NTZ-treated patients and, especially, amongst those who are JCV seropositive but still have low PML risk, but which seems also intimately related to personality traits. |
publishDate |
2013 |
dc.date.issued.fl_str_mv |
2013-12-10 |
dc.date.accessioned.fl_str_mv |
2016-01-24T14:34:51Z |
dc.date.available.fl_str_mv |
2016-01-24T14:34:51Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Plos One. San Francisco: Public Library Science, v. 8, n. 12, 7 p., 2013. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/37076 http://dx.doi.org/10.1371/journal.pone.0082796 |
dc.identifier.issn.none.fl_str_mv |
1932-6203 |
dc.identifier.file.none.fl_str_mv |
WOS000328707400096.pdf |
dc.identifier.doi.none.fl_str_mv |
10.1371/journal.pone.0082796 |
dc.identifier.wos.none.fl_str_mv |
WOS:000328707400096 |
identifier_str_mv |
Plos One. San Francisco: Public Library Science, v. 8, n. 12, 7 p., 2013. 1932-6203 WOS000328707400096.pdf 10.1371/journal.pone.0082796 WOS:000328707400096 |
url |
http://repositorio.unifesp.br/handle/11600/37076 http://dx.doi.org/10.1371/journal.pone.0082796 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Plos One |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
7 |
dc.publisher.none.fl_str_mv |
Public Library Science |
publisher.none.fl_str_mv |
Public Library Science |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
bitstream.url.fl_str_mv |
${dspace.ui.url}/bitstream/11600/37076/1/WOS000328707400096.pdf ${dspace.ui.url}/bitstream/11600/37076/2/WOS000328707400096.pdf.txt |
bitstream.checksum.fl_str_mv |
6040f08dbe202d56c9e98c6e92b935c2 f4b294bc3b9ef688f2273d3dc368b202 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1802764187810660352 |